ClinicalTrials.gg
Not yet recruitingNCT07383155BRIGHT-HBRUpdated Feb 3, 2026

Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes

A Phase 4 interventional study of Anticoagulant Therapy in Percutaneous Coronary Intervention, High Bleeding Risk and Acute Coronary Syndromes, sponsored by Shenyang Northern Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Shenyang Northern Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5,270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital — 5 open to participants now, 5 under way, none of them phase 3. Acute Coronary Syndrome · Shenyang Northern Hospital.

Started
2026
with 2 others
Phase 4
8 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital, this one is one of 3 that started in 2026, is one of 8 in phase 4, and was the 12th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

5 of the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital, or all of them as a file.
02

Study summary

Background. Randomized data on the optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) are lacking.

Methods. BRIGHT-HBR is an investigator-sponsored, open-label, randomized controlled trial comparing bivalirudin vs. unfractionated heparin (UFH) monotherapy in HBR patients with ACS undergoing PCI. A total of 5270 HBR patients with a non-ST-elevation acute coronary syndrome (NSTE-ACS) or recent stabilized ST-segment elevation myocardial infarction (STEMI, ≥48 hours after symptom onset) will be randomized 1:1 to bivalirudin or UFH at 70 sites in China. HBR is defined by the Academic Research Consortium (ARC)-HBR criteria. The primary composite endpoint is net adverse clinical events (NACE) at 30 days, the composite of all-cause death, myocardial infarction, stroke, urgent target-vessel revascularization, or BARC types 2, 3 or 5 bleeding, and the major secondary endpoint is BARC types 2, 3 or 5 bleeding. The study is powered to demonstrate that bivalirudin is superior to UFH monotherapy for NACE in ACS patients with HRB at 30 days after PCI.

Conclusions. The BRIGHT-HBR randomized trial aims to provide evidence on whether bivalirudin reduces the incidence of NACE and clinically relevant bleeding compared with UFH monotherapy in patients with ACS who are at HBR undergoing PCI.

Read the detailed description

Study design BRIGHT-HBR is an investigator-sponsored, prospective, multicenter, open-label, active-controlled randomized trial. A total of 5,270 patients with NSTE-ACS and stabilized recent STEMI who are at HBR and are undergoing PCI with radial artery access will be enrolled at 70 sites in China. Patients are randomized 1:1 to two arms: bivalirudin vs. UFH monotherapy, with GPI reserved for bailout use in each group. The trial is powered to demonstrate the superiority of bivalirudin compared with UFH in reducing the 30-day rate of net adverse clinical events (NACE), the composite of all-cause death, MI, stroke, urgent target-vessel revascularization, or bleeding according to the Bleeding Academic Research Consortium (BARC) types 2, 3 or 5 criteria.

Randomization and study treatment Before diagnostic angiography, eligible patients will be randomly assigned in a 1:1 ratio to procedural anticoagulation with bivalirudin or UFH monotherapy. Allocation to treatment will be provided by an interactive web response system in randomly permuted block sizes of 4 or 6, with stratification according to the participating center, which is incorporated within an electronic data capture system.

In the UFH monotherapy group, an intravenous UFH bolus of 70 U/kg will be administered. The ACT will be measured 5 minutes after the first administration, and if the ACT is \<250 seconds (Hemotec assay), an additional intravenous bolus of 1000 U UFH will be administered, to ensure the re-checked ACT is ≥250 seconds prior to PCI.

In the bivalirudin group, an intravenous bolus dose of bivalirudin 0.75 mg/kg will be administered, followed by an intravenous infusion of 1.75 mg/(kg·h). The infusion dose (but not the bolus) is adjusted for renal insufficiency. The estimated glomerular filtration rate (eGFR) will be calculated by the formula: 186 × (serum creatinine [mg/dL])-1.154 × (age)-0.203 × (0.742 if female). For patients with moderate renal impairment (eGFR 30-59 ml/(min·1.73m2), the intravenous infusion dose is unchanged; for patients with severe renal impairment (eGFR \<30 ml/(min·1.73m2), the intravenous infusion dose is reduced to 1.0 mg/(kg·h); for patients undergoing dialysis, the intravenous infusion dose is reduced to 0.25 mg/(kg·h). The ACT will be monitored 5 minutes after the first bivalirudin bolus administration, and if the ACT is \<250 seconds (Hemotec assay), an additional intravenous bolus of 0.3 mg/kg of bivalirudin will be administered to ensure the re-checked ACT is ≥250 seconds prior to PCI. The intravenous bivalirudin infusion is discontinued immediately after PCI.

The PCI procedure is performed using standard techniques. Radial artery access is strongly recommended. PCI is recommended for vessels with a visually assessed coronary artery diameter ≥2.5 mm with stenosis ≥70% or fractional flow reserve (FFR) \<0.80 or ulcerated plaques. Complete revascularization is recommended if it may be safely achieved. PCI of chronic total occlusions (CTO) that are well-collateralized and supply viable myocardium is recommended if, in the opinion of an experienced CTO operator, there is a high likelihood of PCI success without complications or excessive contrast use. Drug-eluting stents should be used absent contraindications. Declaration of the target vessels will be made before PCI. A planned staged procedure in patients with complex or multivessel disease may be completed within 45 days and will not be considered an endpoint event. The intent to stage must be declared and documented at the end of the first procedure. The anticoagulation regimen during the planned staged procedure must be identical with that of the initial procedure. Any unplanned treatment, or a planned reintervention after 45 days will be considered an endpoint event.

Routine administration of a GPI during the procedure is prohibited. The use of intravenous or intracoronary tirofiban (the most widely used GPI in China) is restricted to specific procedural complications, including target vessel slow flow or no-reflow, refractory thrombus, or other thrombotic complications during PCI that cannot otherwise be effectively treated. When indicated, intravenous tirofiban should be initiated with a bolus infusion of 10-25 μg/kg (administered over >5 minutes), followed by a continuous maintenance infusion of 0.15 μg/(kg·min) for up to 18 hours. For patients with an eGFR \<60 mL/min, the maintenance dose should be reduced to 0.075 μg/(kg·min). Alternatively, an intracoronary bolus dose of 500-750 μg may be used, with repeat injections permitted at intervals of 3-5 minutes. The cumulative intracoronary dose should not exceed 1500-2250 μg. Other procedural medications are provided per standard of care.

Prior to the procedure the patient should be treated with aspirin and a standard loading dose followed by a daily dose of either ticagrelor or clopidogrel (ticagrelor strongly preferred). Dual antiplatelet therapy should be continued post-PCI per local standard of care and societal guidelines. Other chronic medications are administered per local standard of care.

Follow-up Clinical follow-up will be scheduled at 1, 3, 6, and 12 months via telephone or clinic visit after randomization. Throughout the study period, patients will be monitored for the occurrence of the following clinical events: death, MI, stroke, any repeat revascularization, and any bleeding.

03

Conditions studied

  • Percutaneous Coronary Intervention
  • High Bleeding Risk
  • Acute Coronary Syndromes
  • Anticoagulant Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Clinical evidence of NSTE-ACS or recent stabilized STEMI (≥48 hours after symptom onset) undergoing PCI
  • The patient meets the ARC criteria for HBR (≥1 major criterion or ≥2 minor criteria)
  • The patient or legal representative has been fully informed and written has been obtained

Exclusion criteria

Exclusion Criteria:

  • STEMI patients within 48 hours of symptom onset
  • CABG or PCI within the prior 6 months, including for the present clinical syndrome
  • Cardiogenic shock
  • Coronary artery disease unsuitable for revascularization or requiring CABG
  • Confirmed or suspected aortic dissection
  • Treatment with a glycoprotein IIb/IIIa inhibitor within 2 hours prior to the PCI (use of intravenous heparin prior to or at the time of randomization is acceptable)
  • Allergy to UFH, bivalirudin, aspirin, clopidogrel, ticagrelor, or contrast agents that cannot be adequately pre-medicated, or any prior anaphylaxis to these agents
  • Any non-cardiac conditions with an expected of ≤12 months
  • Patients deemed by the investigator to be clinically unsuitable for coronary angiography and PCI, or who are unlikely to be able to comply with the protocol requirements, including medication adherence and follow-up visits
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,270 participants (estimated)

Study arms

  • Experimental
    Group 1

    Bivalirudin

    Drug: Anticoagulant Therapy

  • Active comparator
    Group 2

    Unfractionated heparin monotherapy

    Drug: Anticoagulant Therapy

Interventions

  • DrugAnticoagulant Therapy

    The optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS)

06

What researchers measure

Primary outcomes

  1. Net adverse clinical events (NACE) at 30 days

    The composite of all-cause death, MI, stroke, urgent target-vessel revascularization, or BARC types 2, 3 or 5 bleeding

    Time frame: 30 days post PCI

Secondary outcomes

  1. BARC types 2, 3 or 5 bleeding at 30 days

    Time frame: 30 days post PCI

  2. NACE at 12 months

    Time frame: 1 year post PCI

  3. Each individual component of NACE at 30 days and 12 months

    Time frame: 30 days and 1 year post PCI

  4. Major adverse cardiac and cerebral events (MACCE) at 30 days and 12 months

    Composite of all-cause death, MI, stroke, or urgent target-vessel revascularization

    Time frame: 30 days and 1 year post PCI

  5. BARC types 1, 2, 3, or 5 bleeding at 30 days and 12 months

    Time frame: 30 days and 1 year post PCI

  6. BARC types 3 or 5 bleeding at 30 days and 12 months

    Time frame: 30 days and 1 year post PCI

  7. Definite/probable stent thrombosis at 30 days and 12 months

    Time frame: 30 days and 1 year post PCI

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2027, 22 months later.

Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 22 months is below that.

Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2026
First posted
Feb 3, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07383155
Lead sponsor
Shenyang Northern Hospital
Responsible party
Han Yaling (Professor, Shenyang Northern Hospital) — Principal investigator
First posted
Feb 3, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 3, 2026

Study contacts

Yaling Han, MD
Contact
hanyaling@263.net
86-24-28897310

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion